Abstract
Netarsudil, a rho kinase inhibitor, has recently acquired approval for use in adults in the United States to lower intraocular pressure (IOP) in patients with glaucoma. There remains limited data on the effectiveness and safety profile of Netarsudil in children.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
